Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00397891 |
Evaluate safety, tolerability, and phamacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
Condition | Intervention | Phase |
---|---|---|
Alzheimer Disease |
Drug: bapineuzumab |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease |
Estimated Enrollment: | 24 |
Study Start Date: | October 2006 |
Study Completion Date: | October 2008 |
Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
bapineuzumab 0.15 mg/kg or placebo
|
Drug: bapineuzumab
The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
|
2: Experimental
bapineuzumab 0.5 mg/kg or placebo
|
Drug: bapineuzumab
The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
|
3: Experimental
bapineuzumab 1.0 mg/kg or placebo
|
Drug: bapineuzumab
The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
|
Ages Eligible for Study: | 50 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria
Japan, Chiba | |
2-1-1, Tomioka, Urayasu-shi, Chiba, Japan, 279-0021 | |
Japan, Saitama | |
Koshigaya, Saitama, Japan, 343-0032 | |
Japan, Shizuoka | |
1-20-1, Handayam, Hamamatsu-shi, Shizuoka, Japan, 431-3192 | |
Izunokuni, Shizuoka, Japan, 410-2295 | |
Japan, Tokyo | |
3-1-3, Hongo, Bunkyo-ku, Tokyo, Japan, 113-8431 | |
3-3-20, Shinsuna, Koto-ku, Tokyo, Japan, 136-0075 |
Study Director: | Medical Monitor | Wyeth |
Responsible Party: | Wyeth ( Wyeth (Registry Contact: Clinical Trial Registry Specialist) ) |
Study ID Numbers: | 3133K1-102 |
Study First Received: | November 8, 2006 |
Last Updated: | March 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00397891 History of Changes |
Health Authority: | Japan: Pharmaceuticals and Medical Devices Agency |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Neurodegenerative Diseases |
Brain Diseases Dementia Cognition Disorders Delirium |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Nervous System Diseases Alzheimer Disease Central Nervous System Diseases |
Neurodegenerative Diseases Tauopathies Brain Diseases Dementia |